A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

Completed · Phase 3 · Has a placebo group

Conditions studied: Migraine, Migraine With Aura, Migraine Without Aura

In brief

Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

Key facts

Study ID
NCT04940390
Run by
Satsuma Pharmaceuticals, Inc.
People needed
1591
Starts
2021-06-30
Expected to finish
2022-10-26
Last updated by the study team
2023-11-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.